| Expression pattern: |
UP |
| Associated gene: |
PIK3R1, BRCA1 |
| Associated microRNA: |
miR-198 |
| Biological function: |
Enhances cisplatin resistance, promotes DNA damage repair, inhibits apoptosis, and increases cell viability/colony formation and xenograft tumor growth under CDDP treatment. |
| Molecular mechanism: |
Acts as a ceRNA that sponges miR-198 to relieve repression of PIK3R1, thereby activating PI3K/AKT signaling and promoting DNA damage repair (BRCA1-related) and cisplatin resistance. |
| Biological pathway or process: |
PI3K/AKT (promotes); apoptosis (inhibits); drug resistance (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; IF (Immunofluorescence); Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; ROC Analysis; Survival Analysis; Clinical Sample Validation; Cohort Study; Bioinformatics Analysis |
| Clinical significance: |
Upregulation of circAKT3 in GC patients receiving CDDP therapy is associated with aggressive characteristics and is an independent risk factor for decreased disease-free survival (DFS); circAKT3 shows good predictive performance for CDDP resistance (AUC 91%). |
| Description: |
circAKT3 (hsa_circ_0000199) is up-regulated in cisplatin-resistant gastric cancer tissues/cells and promotes CDDP resistance. It acts mainly in the cytoplasm as a miR-198 sponge to upregulate PIK3R1, activate PI3K/AKT signaling, enhance DNA damage repair (BRCA1-related), and inhibit apoptosis; high circAKT3 predicts worse DFS and may serve as a biomarker/target for CDDP-treated GC. |
| Confidence score: |
0.8908 |